IsoTis BV
This article was originally published in Start Up
Executive Summary
Uniting engineering with biology is the aim of IsoTis BV. The start-up has a portfolio of 33 patents all related to what the company terms "substitution medicine", the replacement or repair of human tissue.
You may also be interested in...
Biomaterials: Mechanical Engineering Meets Biology
Start-ups developing man-made surrogates for living processes hope to achieve the alchemy of turning base materials into human tissue.
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.